Accelerating Biologic Discovery with Confidence

Get Started

Mosaic Biosciences is an integrated biologics discovery partner advancing complex antibody and protein therapeutics. Our platform combines antibody discovery, protein engineering, and translational pharmacology to move programs from concept to candidate selection with scientific rigor and speed.

Our Biologic Discovery Solutions

Mosaic delivers integrated discovery programs across antibody engineering, protein science, cell-based screening, and pharmacology supporting progression from target to candidate.

Explore All Solutions

Why Mosaic for Biologic Discovery

Mosaic integrates advanced antibody libraries, protein engineering, function-first screening, and early developability assessment to accelerate progression from target identification to candidate selection.

End-to-end discovery integration

Freedom to operate

Function-first screening strategy

Complex protein expertise

Early developability focus

FHC technology access

Leadership with Proven Biologic Discovery Impact

Mosaic’s scientific leadership team has built platforms, advanced clinical candidates, and led discovery programs at leading biotechnology and pharmaceutical companies.

Meet Our Leadership

Eric Furfine, PhD

Chief Scientific Officer

Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.

Alexei Kazantsev, PhD

Sr. Director Protein Design and Engineering

30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.

Tracy Mullen

Chief Strategy Officer

Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.

Scott Glaser PhD

SVP, Biologics Discovery